Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co., Inc.

http://www.merck.com

Latest From Merck & Co., Inc.

Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases

EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.

Financing Business Strategies

Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.

Reimbursement Medicare

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.

Medicare Reimbursement

Roche Continues To Cast Its Collaborations Net Wide

The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abmaxis
    • Acacia Biosciences
    • Acceleron Pharma Inc.
    • Afferent Pharmaceuticals
    • ArQule, Inc.
    • Avecia Biologics Limited
    • Banyu Pharmaceutical Co., Ltd.
    • Calporta Therapeutics
    • cCAM Biotherapeutics Ltd.
    • Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
    • Calixa Therapeutics, Inc.
    • Optimer Pharmaceuticals, Inc.
    • Trius Therapeutics, Inc.)
    • Idenix Pharmaceuticals, Inc.
    • Immune Design Corporation
    • Inspire Pharmaceuticals, Inc.
    • IOmet Pharma
    • iOnctura SA
    • Integrated Therapeutics Group
    • Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
    • MSD
    • MSD K.K. (Japan)
    • Nobilon International BV
    • Novacardia
    • OncoEthix SA
    • OncoImmune, Inc.
    • Organon BioSciences
    • Peloton Therapeutics, Inc.
    • Pandion Therapeutics, Inc.
    • Rigontec GmbH
    • Schering-Plough Corporation
    • SmartCells, Inc.
    • Tilos Therapeutics, Inc.
    • Vallee S.A.
    • Viralytics Limited (ASX:VLA)
    • Themis Biosciences GmbH
UsernamePublicRestriction

Register